| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| Pubmed | 1.06e-04 | 79 | 7 | 2 | 25921334 | ||
| CoexpressionAtlas | FacebaseRNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_1000_k-means-cluster#1 | 5.78e-05 | 255 | 7 | 3 | Facebase_RNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_1000_K1 | |
| CoexpressionAtlas | kidney_P1_CapMes_Crym_k-means-cluster#3_top-relative-expression-ranked_1000 | 2.56e-04 | 75 | 7 | 2 | gudmap_kidney_P1_CapMes_Crym_k3_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_500_k-means-cluster#4 | 7.54e-04 | 129 | 7 | 2 | Facebase_RNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_500_K4 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Medial Nasal Eminence_top-relative-expression-ranked_2500_k-means-cluster#1 | 7.72e-04 | 614 | 7 | 3 | Facebase_RNAseq_e10.5_Medial Nasal Eminence_2500_K1 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_2500_k-means-cluster#5 | 9.44e-04 | 658 | 7 | 3 | Facebase_RNAseq_ratio_e10.5_MandibularArch_vs_MaxillaryArch_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Olfactory Pit_top-relative-expression-ranked_2500_k-means-cluster#2 | 9.49e-04 | 659 | 7 | 3 | Facebase_RNAseq_e10.5_Olfactory Pit_2500_K2 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Olfactory Placode_top-relative-expression-ranked_2500_k-means-cluster#4 | 1.05e-03 | 683 | 7 | 3 | Facebase_RNAseq_e9.5_Olfactory Placode_2500_K4 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Mandibular Arch_top-relative-expression-ranked_2500_k-means-cluster#5 | 1.08e-03 | 688 | 7 | 3 | Facebase_RNAseq_e10.5_Mandibular Arch_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_top-relative-expression-ranked_2500_k-means-cluster#4 | 1.23e-03 | 721 | 7 | 3 | Facebase_RNAseq_ratio_e9.5_MandibularArch_vs_MaxillaryArch_2500_K4 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Facial Mesenchyne_top-relative-expression-ranked_2500_k-means-cluster#5 | 1.24e-03 | 722 | 7 | 3 | Facebase_RNAseq_e9.5_Facial Mesenchyne_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Paraxial Mesoderm_top-relative-expression-ranked_2500_k-means-cluster#3 | 1.28e-03 | 730 | 7 | 3 | Facebase_RNAseq_e8.5_Paraxial Mesoderm_2500_K3 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_2500_k-means-cluster#5 | 1.29e-03 | 732 | 7 | 3 | Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#5 | 1.34e-03 | 743 | 7 | 3 | Facebase_RNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Maxillary Arch_top-relative-expression-ranked_2500_k-means-cluster#2 | 1.36e-03 | 747 | 7 | 3 | Facebase_RNAseq_e9.5_Maxillary Arch_2500_K2 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#2 | 1.36e-03 | 747 | 7 | 3 | Facebase_RNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_2500_K2 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Central Eminence_top-relative-expression-ranked_2500_k-means-cluster#3 | 2.28e-03 | 893 | 7 | 3 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Central Eminence_2500_K3 | |
| ToppCell | kidney_cells-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Medullary_Thick_Ascending_Limb_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.62e-06 | 163 | 7 | 3 | cab65dabeea58141c649e4fec5e0123beb3de1b3 | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_1|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 1.93e-06 | 173 | 7 | 3 | efb8072475000888efe088d00e870c56ffad4172 | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 1.97e-06 | 174 | 7 | 3 | 58300d64d3b6fd9ba1b6c87ea83b2777eb6be2f4 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_B-B_cell-B_c04-SOX5-TNFRSF1B|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.11e-04 | 144 | 7 | 2 | fca32b38d23fa4d213e553b929604a2796e9a929 | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_1|368C / Donor, Lineage, Cell class and subclass (all cells) | 2.23e-04 | 148 | 7 | 2 | 80470353e12599440f711b6e107730763376d04d | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_naive-B_naive-9|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.29e-04 | 150 | 7 | 2 | d9931507257c64ead4a53786e6822f51962c6015 | |
| ToppCell | 10x5'v1-week_12-13-Hematopoietic-HSC/MPP_and_pro-HSC/MPP|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 2.64e-04 | 161 | 7 | 2 | 46b5d80d2d521fb69752aba4c10383e715a32002 | |
| ToppCell | 10x_3'_v3-thymus_(10x_3'_v3)-myeloid-myeloid_dendritic-dendritic_cell|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.74e-04 | 164 | 7 | 2 | 3088d5fa240d2f4a6e21281f7ac932aea2f9af49 | |
| ToppCell | 10x_3'_v3-thymus_(10x_3'_v3)-myeloid-myeloid_dendritic|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.81e-04 | 166 | 7 | 2 | 479391aa6c09aa070b716128ab51b8fec0aea22d | |
| ToppCell | 3'_v3-GI_small-bowel-Lymphocytic_B|GI_small-bowel / Manually curated celltypes from each tissue | 2.88e-04 | 168 | 7 | 2 | 5535c1b8b7fde7b59a1bc0580cebdfa963aa1c39 | |
| ToppCell | IIH-naiveBc|IIH / Condition, Cell_class and T cell subcluster | 2.88e-04 | 168 | 7 | 2 | 8450ed6720d308c711dfbc76652e5821be7b8e93 | |
| ToppCell | IIH-naiveBc-|IIH / Condition, Cell_class and T cell subcluster | 2.88e-04 | 168 | 7 | 2 | 27b500f79aedc4669988670c92ff1a47dcbdf2a0 | |
| ToppCell | 3'_v3-GI_small-bowel-Lymphocytic_B-Memory_B_cells|GI_small-bowel / Manually curated celltypes from each tissue | 2.88e-04 | 168 | 7 | 2 | 8e025bb0541746e232b77ac0e31412ae71420c47 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.98e-04 | 171 | 7 | 2 | b6ee3a6bc436df5e9129b8e0bed9fa3078a4ff23 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.98e-04 | 171 | 7 | 2 | c3e3ea09c73050372314a89b282e36ba5f339d73 | |
| ToppCell | facs-Marrow-Granulocytes-3m-Myeloid-macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.01e-04 | 172 | 7 | 2 | 7fb31ccbcd0204c3612986a6bc20d57ed6825e9c | |
| ToppCell | droplet-Liver-nan-3m-Myeloid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.01e-04 | 172 | 7 | 2 | bb96c896d125e10b71e94e2bdad243899045af5c | |
| ToppCell | droplet-Liver-nan-3m-Myeloid-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.01e-04 | 172 | 7 | 2 | 1f335ccb92b22d0412954e8fc3af212f96410b67 | |
| ToppCell | facs-Marrow-Granulocytes-3m-Myeloid-CD4+_macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.01e-04 | 172 | 7 | 2 | 2a4614b3d25e8c6b095e6992d8ca35371dcdb5e1 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Neuronal-interneuron|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.12e-04 | 175 | 7 | 2 | 65571d775d26a40e979dbf290a8e4320c0d9fb3f | |
| ToppCell | IIH-mDC1-|IIH / Condition, Cell_class and T cell subcluster | 3.15e-04 | 176 | 7 | 2 | bb80a3e595d071f6cc8b042984b8d9490e377eef | |
| ToppCell | normal_Pleural_Fluid-Myeloid_cells-CD163+CD14+_DCs|normal_Pleural_Fluid / Location, Cell class and cell subclass | 3.15e-04 | 176 | 7 | 2 | 7a74217b7fa1032b918f00a3972dff5fab74671a | |
| ToppCell | IIH-mDC1|IIH / Condition, Cell_class and T cell subcluster | 3.15e-04 | 176 | 7 | 2 | a75dc132a1061006fd1cb305bd314784fca07ea6 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_naive-B_naive-2|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.34e-04 | 181 | 7 | 2 | 75035a3211e524bb659b82e6979f7d3a3121ae70 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_B-B_cell|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.37e-04 | 182 | 7 | 2 | ccd729388d997cc45071175cb0c3db6d0790eaf8 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_B|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.45e-04 | 184 | 7 | 2 | d18e94839a62fca536ae1630c154e5d0aafc44c5 | |
| ToppCell | 3'-Child09-12-SmallIntestine-Hematopoietic-B_cells-FCRL4+_Memory_B|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.45e-04 | 184 | 7 | 2 | 95cf125127658c4c04445c61809d1aed21ee1f83 | |
| ToppCell | normal-na-Myeloid-conventional_dendritic_cell-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 3.48e-04 | 185 | 7 | 2 | 67e881a89a491665b8c612fff084c202c0c79235 | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-21m-Epithelial-luminal_epithelial_cell_of_mammary_gland|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.52e-04 | 186 | 7 | 2 | 02fbb02c495e7d64c4ab50e42e5197782f2c0816 | |
| ToppCell | Control-Lymphoid-B|Lymphoid / Disease state, Lineage and Cell class | 3.56e-04 | 187 | 7 | 2 | 4e64be635f445276e71f2937f33f041c3a4204ab | |
| ToppCell | IPF-Lymphoid-B|Lymphoid / Disease state, Lineage and Cell class | 3.56e-04 | 187 | 7 | 2 | af1327559f7e01bec070881cae52834917c3da65 | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_B-Memory_B_cells|GI_small-bowel / Manually curated celltypes from each tissue | 3.60e-04 | 188 | 7 | 2 | ab1384e6f71053946368502282aeebf1ba92d33e | |
| ToppCell | normal-na-Lymphocytic_B-B_atypical|normal / PBMC cell types (v2) per disease, treatment status, and sex | 3.60e-04 | 188 | 7 | 2 | 13653481d64c7a1ad833d738a3ee0bb9def7cec7 | |
| ToppCell | normal-na-Lymphocytic_B-B_atypical-female|normal / PBMC cell types (v2) per disease, treatment status, and sex | 3.60e-04 | 188 | 7 | 2 | e5ab89030783461e9367ab87c353fb5c31911020 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_atypical-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.60e-04 | 188 | 7 | 2 | ef05d2fb17fd427d46d454e67073e0e1b45bb24c | |
| ToppCell | 3'_v3-blood-Myeloid_Dendritic-DC1|blood / Manually curated celltypes from each tissue | 3.60e-04 | 188 | 7 | 2 | 411d4dd5c9dee7ebd8db352640cf009e7b033ba9 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_atypical|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.64e-04 | 189 | 7 | 2 | ebaf722738c71d5f33f72341f801c6880f4aee14 | |
| ToppCell | CTRL-Lymphoid-B_cell|Lymphoid / Disease state, Lineage and Cell class | 3.64e-04 | 189 | 7 | 2 | 14f3a8c0f4f057ad4e6839b4c3eeaf956d6dc92e | |
| ToppCell | COVID_vent-Lymphocytic-B_cell|COVID_vent / Disease condition, Lineage, Cell class and subclass | 3.67e-04 | 190 | 7 | 2 | 40b5e9e8f8fd8d84cb5b43e67b49267082348e9f | |
| ToppCell | COVID_vent-Lymphocytic-B_cell-|COVID_vent / Disease condition, Lineage, Cell class and subclass | 3.67e-04 | 190 | 7 | 2 | a37a32dc1b931562a6660074e19d5598efc65284 | |
| ToppCell | COPD-Lymphoid-B|Lymphoid / Disease state, Lineage and Cell class | 3.67e-04 | 190 | 7 | 2 | 1e85ee686ff6dd27c69415d524d54fa825b1daad | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_B-ABC_aged-B_memory|lymph-node_spleen / Manually curated celltypes from each tissue | 3.71e-04 | 191 | 7 | 2 | c3ca8077da8594fb493e47ac4dfbbd20bfc14b37 | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_B-B_atypical|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.75e-04 | 192 | 7 | 2 | 24797e80b1f5b3ea5a0410caaf57ccf2ae9d716e | |
| ToppCell | moderate-Lymphoid-B_cell|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 3.75e-04 | 192 | 7 | 2 | ae3727503c3b9f4695e565fd3161cc33b898f349 | |
| ToppCell | VE-naiveBc-|VE / Condition, Cell_class and T cell subcluster | 3.75e-04 | 192 | 7 | 2 | bca2aec4811627225fccd92abe2f3b1ba729c9ce | |
| ToppCell | VE-naiveBc|VE / Condition, Cell_class and T cell subcluster | 3.75e-04 | 192 | 7 | 2 | 87cdda9a170f6f2fa56d0ed1d3fd2f93bfe09aa1 | |
| ToppCell | VE-pDC-|VE / Condition, Cell_class and T cell subcluster | 3.79e-04 | 193 | 7 | 2 | 583724de588fcde3aeda056138c522dc0225a387 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-B_cell|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.79e-04 | 193 | 7 | 2 | f4135615ee0118eec9e221becdd67888e0c2a112 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.79e-04 | 193 | 7 | 2 | ac227ddabfb3f021b1b39dba73f898517cd5a58e | |
| ToppCell | VE-pDC|VE / Condition, Cell_class and T cell subcluster | 3.79e-04 | 193 | 7 | 2 | bb759dc9ef0ec41d655002f59021d62d62d44289 | |
| ToppCell | severe_COVID-19-B_intermediate|World / disease group, cell group and cell class (v2) | 3.83e-04 | 194 | 7 | 2 | cb346cb186fe80a8f490ae90b2539b3543ba0ca9 | |
| ToppCell | MS-naiveBc-|MS / Condition, Cell_class and T cell subcluster | 3.83e-04 | 194 | 7 | 2 | 1757787246a7862f9709834efc62bac61d70b906 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.83e-04 | 194 | 7 | 2 | 5cd72330c9d9bb21b6c9d5d35085eade101486d1 | |
| ToppCell | MS-naiveBc|MS / Condition, Cell_class and T cell subcluster | 3.83e-04 | 194 | 7 | 2 | aa4aa0a61275610054b583f60d5d41ecc4f88a0d | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_B-B_atypical-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.83e-04 | 194 | 7 | 2 | b8f05efb16fbed7317019efc3da7f97f81e90972 | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_B-ABC_aged-B_memory|lymph-node_spleen / Manually curated celltypes from each tissue | 3.83e-04 | 194 | 7 | 2 | b57ae94a092b58623a244a258b4659a3864542c7 | |
| ToppCell | normal_Pleural_Fluid-B_lymphocytes-Follicular_B_cells|normal_Pleural_Fluid / Location, Cell class and cell subclass | 3.83e-04 | 194 | 7 | 2 | 678da250aa881ff29482bc464affca7a5f360dc5 | |
| ToppCell | critical-Lymphoid-B_cell|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 3.83e-04 | 194 | 7 | 2 | eeae611ab72d602fb545c729a14ef38ce5c47f2c | |
| ToppCell | normal_Pleural_Fluid-B_lymphocytes|normal_Pleural_Fluid / Location, Cell class and cell subclass | 3.83e-04 | 194 | 7 | 2 | a3192698248561462d8d3bdaeabdff563a07019f | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.83e-04 | 194 | 7 | 2 | d852aebf7a763b9a776c4570711f0c759f591910 | |
| ToppCell | control-Lymphocytic-B_cells_1|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 3.87e-04 | 195 | 7 | 2 | ff7956624b36df34e55295b295a71585accf07bd | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_B-Memory_B_cells|lymph-node_spleen / Manually curated celltypes from each tissue | 3.87e-04 | 195 | 7 | 2 | 8b307079cee67fc1df55277d0cab21ea4b97e552 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B-B_cell|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.87e-04 | 195 | 7 | 2 | 481989d2e5bd2582da3d86b0155c4d6615317067 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_B|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.87e-04 | 195 | 7 | 2 | 6108a27523d1b93a7fbe35cb95704a5ad9071e3c | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.91e-04 | 196 | 7 | 2 | 676c56b44ac29f7baecb62f49bb8597cc74c0a88 | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_B-Memory_B_cells|lymph-node_spleen / Manually curated celltypes from each tissue | 3.91e-04 | 196 | 7 | 2 | c450cd6b799932f5cce8326d1079114abeb71e95 | |
| ToppCell | Smart-seq2-lymph_node_(Smart-seq2)-lymphocytic-B_lymphocytic|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.95e-04 | 197 | 7 | 2 | fa3cc33c975648172feabb485c3bdd087f1f8ea7 | |
| ToppCell | mild_COVID-19-cDC|World / disease group, cell group and cell class (v2) | 3.95e-04 | 197 | 7 | 2 | 63e7b040c64f1e28b8db79980c7b580caa7d1b95 | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_B|lymph-node_spleen / Manually curated celltypes from each tissue | 3.95e-04 | 197 | 7 | 2 | 9837bd2cc28b79147fb5d1997631ef953fd020e4 | |
| ToppCell | mild_COVID-19-cDC|mild_COVID-19 / disease group, cell group and cell class (v2) | 3.95e-04 | 197 | 7 | 2 | 44ebd3f967779bb7753fc6dcd9fde6d682f9ccd6 | |
| ToppCell | Monocytes-cDCs|Monocytes / Immune cells in Kidney/Urine in Lupus Nephritis | 3.95e-04 | 197 | 7 | 2 | 15cb9fe1c3bab80bd24728fd9ac7ba385912ac33 | |
| ToppCell | COVID-19_Severe-Lymphoid_B|COVID-19_Severe / Disease group, lineage and cell class | 3.95e-04 | 197 | 7 | 2 | 25303329b051831cf2ed4df68f3948308e5fbd96 | |
| ToppCell | mild-pDC|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.95e-04 | 197 | 7 | 2 | 0cb00daa6943f7a7fb34a8fdf51188646af65686 | |
| ToppCell | mild_COVID-19-B_intermediate|World / disease group, cell group and cell class (v2) | 3.95e-04 | 197 | 7 | 2 | e909b898b7458071f176b6c04356ea3540589153 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.95e-04 | 197 | 7 | 2 | 5c67ed18fb92aec73c79f4db6d80cec777d9ba44 | |
| ToppCell | control-B_naive|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.99e-04 | 198 | 7 | 2 | c012b8fbfa8bbc5014217f47acf9177470d8a65a | |
| ToppCell | mLN-(2)_B_cell-(22)_B_cell_memory|mLN / shred on region, Cell_type, and subtype | 3.99e-04 | 198 | 7 | 2 | 4d189df1db5b41306e9653436d7d7e75ff5afa06 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.99e-04 | 198 | 7 | 2 | c01091ef18e096d792ea2a7a715764a5b215355f | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.99e-04 | 198 | 7 | 2 | 6d18b45eda4014759e6dd282d78ffd28df8a6044 | |
| ToppCell | MS-IIF-Lymphocyte-B-B_intermediate|IIF / Disease, condition lineage and cell class | 3.99e-04 | 198 | 7 | 2 | d6b533c5e1d55e13b1e87ce3dbacb1564bcdcc64 | |
| ToppCell | severe-pDC|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.99e-04 | 198 | 7 | 2 | 3c4820a8391088682fb3e47b914f872533bae227 | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_B|lymph-node_spleen / Manually curated celltypes from each tissue | 3.99e-04 | 198 | 7 | 2 | 1780fa1725a321041094e8c4430673c0a4f3d407 | |
| ToppCell | severe-pDC|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 3.99e-04 | 198 | 7 | 2 | 22da4a29b9ff8b94d98bc69b4632a2a58d5dd9e6 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.99e-04 | 198 | 7 | 2 | 8ab40fae14fe02e39bc8c8da187a5cd60c787643 | |
| ToppCell | mLN-B_cell-B_cell_memory|mLN / Region, Cell class and subclass | 3.99e-04 | 198 | 7 | 2 | 6dc155ee487abb1319a60a7a70e84c28c9851985 | |
| ToppCell | Tracheal-NucSeq-Stromal-Schwann-Schwann_Myelinating|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.03e-04 | 199 | 7 | 2 | 4e4bdcd2e8b518156d5ebd294804180acaa3566b | |
| ToppCell | mLN-(2)_B_cell|mLN / shred on region, Cell_type, and subtype | 4.03e-04 | 199 | 7 | 2 | 9464c8c72a6b2e14a27b413cc1f5d64550212776 | |
| ToppCell | Bronchial-10x5prime-Epithelial-Epi_airway_ciliated-Deuterosomal|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 4.03e-04 | 199 | 7 | 2 | 92778939e9d06599c7d06cfd8f4362b97ed0606b | |
| ToppCell | mLN-B_cell|mLN / Region, Cell class and subclass | 4.03e-04 | 199 | 7 | 2 | 99c7d157a1e819ff86c526ffd9b7036ed3514cae | |
| ToppCell | mild-B_naive|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 4.07e-04 | 200 | 7 | 2 | 222789b897e2a683bbfd1d00b6fd8705015d90df | |
| ToppCell | MS-Multiple_Sclerosis-Lymphocyte-B-B_intermediate|Multiple_Sclerosis / Disease, condition lineage and cell class | 4.07e-04 | 200 | 7 | 2 | e945dd467dc90b8042982051d1bf76b72a4baf5b | |
| ToppCell | Neuronal|World / cells hierarchy compared to all cells using T-Statistic | 4.07e-04 | 200 | 7 | 2 | 48d801219bc771d6c7e151dc88ca4c179988de85 | |
| ToppCell | MS-Multiple_Sclerosis-Lymphocyte-B|Multiple_Sclerosis / Disease, condition lineage and cell class | 4.07e-04 | 200 | 7 | 2 | 082b3be49fa9d65ed8351d4e80680583f8735207 | |
| ToppCell | severe-B_naive|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 4.07e-04 | 200 | 7 | 2 | 0e86f52b6e146d9bbc728d8fb176fc2b53696558 | |
| Computational | Neighborhood of UBE2N | 1.98e-03 | 154 | 5 | 2 | GCM_UBE2N | |
| Computational | Neighborhood of MYST2 | 2.47e-03 | 172 | 5 | 2 | GCM_MYST2 | |
| Computational | Neighborhood of MLL | 2.52e-03 | 174 | 5 | 2 | GCM_MLL | |
| Computational | Neighborhood of RAB10 | 2.58e-03 | 176 | 5 | 2 | GCM_RAB10 | |
| Drug | radicicol, diheterospora chlamydosporia; Up 200; 0.1uM; HL60; HT_HG-U133A | 1.23e-03 | 177 | 7 | 2 | 2679_UP | |
| Drug | Prochlorperazine dimaleate [84-02-6]; Down 200; 6.6uM; PC3; HT_HG-U133A | 1.44e-03 | 192 | 7 | 2 | 6664_DN | |
| Drug | Iopanoic acid [96-83-3]; Up 200; 7uM; HL60; HT_HG-U133A | 1.47e-03 | 194 | 7 | 2 | 2965_UP | |
| Drug | Kynurenine, 3-hydroxy (R,S) [2147-61-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A | 1.47e-03 | 194 | 7 | 2 | 5641_DN | |
| Drug | Tacrine hydrochloride hydrate [1684-40-8]; Up 200; 15.8uM; HL60; HT_HG-U133A | 1.47e-03 | 194 | 7 | 2 | 1278_UP | |
| Drug | estradiol, USP; Up 200; 0.1uM; HL60; HT_HG-U133A | 1.49e-03 | 195 | 7 | 2 | 2668_UP | |
| Drug | pentamidine isethionate salt; Down 200; 100uM; MCF7; HG-U133A | 1.52e-03 | 197 | 7 | 2 | 639_DN | |
| Drug | Ganciclovir [82410-32-0]; Down 200; 15.6uM; PC3; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 6289_DN | |
| Drug | Ethoxyquin [91-53-2]; Down 200; 18.4uM; HL60; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2559_DN | |
| Drug | Ramipril [87333-19-5]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 3572_DN | |
| Drug | Mebendazole [31431-39-7]; Down 200; 13.6uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2300_DN | |
| Drug | Methyldopa (L,-) [555-30-6]; Down 200; 19uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 3234_DN | |
| Drug | Piperacillin sodium salt [59703-84-3]; Down 200; 7.4uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 3939_DN | |
| Drug | Reserpinic acid hydrochloride; Up 200; 9.2uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 4948_UP | |
| Drug | Lidocaone hydrochloride [73-78-9]; Down 200; 14.8uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 1499_DN | |
| Drug | Testosterone propionate [57-85-2]; Up 200; 11.6uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 2649_UP | |
| Drug | Trimethoprim [738-70-5]; Down 200; 13.8uM; HL60; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 2345_DN | |
| Drug | Merbromin [129-16-8]; Up 200; 5uM; HL60; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 2577_UP | |
| Drug | Carbimazole [22232-54-8]; Up 200; 21.4uM; HL60; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 2437_UP | |
| Drug | Trimethadione [127-48-0]; Down 200; 28uM; HL60; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 2486_DN | |
| Drug | Vitexin [3681-93-4]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 4413_UP | |
| Drug | (+,-)-Synephrine [94-07-5]; Down 200; 24uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 3578_DN | |
| Drug | Isocarboxazid [59-63-2]; Up 200; 17.2uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 4706_UP | |
| Drug | Tetramisole hydrochloride [16595-80-5]; Up 200; 16.6uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 4412_UP | |
| Drug | Methoxy-6-harmalan [3589-73-9]; Down 200; 18.6uM; PC3; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 6355_DN | |
| Drug | iloprost; Up 200; 1uM; SKMEL5; HG-U133A | 1.55e-03 | 199 | 7 | 2 | 496_UP | |
| Drug | Meprylcaine hydrochloride [956-03-6]; Down 200; 14.8uM; HL60; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 6123_DN | |
| Drug | Vitexin [3681-93-4]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 1.57e-03 | 200 | 7 | 2 | 4413_DN | |
| Drug | 5186223; Up 200; 12uM; MCF7; HT_HG-U133A_EA | 1.57e-03 | 200 | 7 | 2 | 885_UP | |
| Drug | GBR 12909 dihydrochloride [67469-78-7]; Down 200; 7.6uM; MCF7; HT_HG-U133A | 1.57e-03 | 200 | 7 | 2 | 3240_DN | |
| Drug | Guanadrel sulfate [22195-34-2]; Up 200; 7.6uM; HL60; HT_HG-U133A | 1.57e-03 | 200 | 7 | 2 | 2575_UP | |
| Drug | Nialamide [51-12-7]; Down 200; 13.4uM; PC3; HT_HG-U133A | 1.57e-03 | 200 | 7 | 2 | 4525_DN | |
| Drug | Netilmicin sulfate [56931-57-2]; Down 200; 2.8uM; MCF7; HT_HG-U133A | 1.57e-03 | 200 | 7 | 2 | 6005_DN | |
| Disease | Seizures | 1.11e-03 | 218 | 7 | 2 | C0036572 | |
| Disease | white matter hyperintensity measurement | 2.12e-03 | 302 | 7 | 2 | EFO_0005665 | |
| Disease | Intellectual Disability | 4.57e-03 | 447 | 7 | 2 | C3714756 | |
| Disease | parental longevity | 5.56e-03 | 494 | 7 | 2 | EFO_0007796 | |
| Disease | attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement | 1.41e-02 | 801 | 7 | 2 | EFO_0003888, EFO_0007052, MONDO_0002491 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| PKVEIMPPPPKPKDM | 221 | P11182 | |
| MPPPPKPKDMTVPIL | 226 | P11182 | |
| LSPPLPPKKVMICMP | 236 | Q9C0D0 | |
| MEPQKIMPPSKPHPP | 1 | Q8TC84 | |
| SPKPTCMVPPMPHSP | 461 | O94966 | |
| PRPKPAVPMKPMSIN | 21 | Q9UH03 | |
| MKPPPKPTMPSRPIA | 141 | Q9H0E3 | |
| KPRKPPMVMTPPTCT | 496 | Q9Y6X0 |